Author:
Gabriel Emmanuel M.,Kim Minhyung,Fisher Daniel T.,Powers Colin,Attwood Kristopher,Bagaria Sanjay P.,Knutson Keith L.,Skitzki Joseph J.
Abstract
AbstractDespite advances in therapy for melanoma, heterogeneous responses with limited durability represent a major gap in treatment outcomes. The purpose of this study was to determine whether alteration in tumor blood flow could augment drug delivery and improve antitumor responses in a regional model of melanoma. This approach to altering tumor blood flow was termed “dynamic control.” Dynamic control of tumor vessels in C57BL/6 mice bearing B16 melanoma was performed using volume expansion (saline bolus) followed by phenylephrine. Intravital microscopy (IVM) was used to observe changes directly in real time. Our approach restored blood flow in non-functional tumor vessels. It also resulted in increased chemotherapy (melphalan) activity, as measured by formation of DNA adducts. The combination of dynamic control and melphalan resulted in superior outcomes compared to melphalan alone (median time to event 40.0 vs 25.0 days, respectively, p = 0.041). Moreover, 25% (3/12) of the mice treated with the combination approach showed complete tumor response. Importantly, dynamic control plus melphalan did not result in increased adverse events. In summary, we showed that dynamic control was feasible, directly observable, and augmented antitumor responses in a regional model of melanoma. Early clinical trials to determine the translational feasibility of dynamic control are ongoing.
Funder
National Center for Advancing Translational Sciences
National Cancer Institute
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. SEER Cancer Statistics Factsheets: Melanoma of the Skin (National Cancer Institute, Bethesda MD). https://seer.cancer.gov/statfacts/html/melan.html. Accessed March 4, 2020.
2. Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol.17, 1471–1474 (2010).
3. Read, R. L. et al. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann. Surg. Oncol.22, 475–481 (2015).
4. Kang, J. C. et al. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol.23, 4764–4770 (2005).
5. Pawlik, T. M. et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann. Surg. Oncol.12, 587–596 (2005).
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献